Krystal Biotech (KRYS) Assets Average (2017 - 2026)

Krystal Biotech has reported Assets Average for 10 years, with the latest figure at $1.4 billion in Q2 2026.

• Assets Average for Q2 2026 came in at $1.4 billion, up 30.95% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 30.95% YoY), and the FY2025 annual result was $1.2 billion, up 27.5% from the prior year.
• Assets Average improved to $1.4 billion in Q2 2026, from $1.4 billion in the prior quarter.
• Over five years, Assets Average peaked at $1.4 billion in Q2 2026 and troughed at $545.1 million in Q1 2023.
• A 5-year average of $901.9 million and a median of $860.7 million in 2024 frame the typical range for Assets Average.
• The widest annual swing landed in 2022, when Assets Average jumped 64.91%; it then declined 12.3% in 2023.
• A 5-year view of Assets Average shows it stood at $567.4 million in 2022, then surged by 41.76% to $804.4 million in 2023, then climbed by 26.7% to $1.0 billion in 2024, then gained by 26.29% to $1.3 billion in 2025, then increased by 12.58% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.4 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.3 billion in Q4 2025.